Vestronidase Alfa-vjbk Injection (MEPSEVII)

Mepsevii (vestronidase alfa‑vjbk) is covered only for FDA‑approved treatment of mucopolysaccharidosis type VII (MPS VII) when diagnosis is confirmed by deficient beta‑glucuronidase activity or by molecular genetic testing and the drug is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or lysosomal storage disorder specialist; use for other indications is not covered. Coverage is limited to up to 4 mg/kg IV no more frequently than every 2 weeks with authorization up to 12 months, and requires documentation of diagnostic test results, specialist involvement, patient weight/dosing, and applicable safety criteria for initial and continued coverage.

"Frequency limited to no more frequently than once every 2 weeks."

Sign up to see full coverage criteria, indications, and limitations.